Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) Research & Development (2016 - 2025)

Ocugen (OCGN) has disclosed Research & Development for 12 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 28.7% year-over-year to $10.7 million, compared with a TTM value of $39.8 million through Dec 2025, up 23.73%, and an annual FY2025 reading of $39.8 million, up 23.73% over the prior year.
  • Research & Development was $10.7 million for Q4 2025 at Ocugen, down from $11.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.3 million in Q4 2022 and bottomed at $2.9 million in Q1 2021.
  • Average Research & Development over 5 years is $10.1 million, with a median of $8.7 million recorded in 2024.
  • The sharpest move saw Research & Development surged 1056.72% in 2021, then plummeted 63.48% in 2023.
  • Year by year, Research & Development stood at $7.1 million in 2021, then skyrocketed by 199.92% to $21.3 million in 2022, then tumbled by 63.48% to $7.8 million in 2023, then rose by 6.57% to $8.3 million in 2024, then grew by 28.7% to $10.7 million in 2025.
  • Business Quant data shows Research & Development for OCGN at $10.7 million in Q4 2025, $11.1 million in Q3 2025, and $8.4 million in Q2 2025.